NP:NYSENeptune Insurance Holdings Inc. Analysis
Data as of 2026-05-19 - not real-time
$27.22
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Neptune Insurance is trading at $27.22, just above its 20‑day SMA of $27.17 and comfortably over the 50‑day and 200‑day averages, while the RSI sits at a neutral 51.8 and the MACD has turned bearish with a negative histogram. Volatility remains elevated at 72.6% over the past 30 days and the stock’s beta of 0.85 suggests slightly lower market sensitivity, yet the price sits far above the DCF‑derived fair value of $8.13, implying a significant overvaluation. The forward PE of 42.4 dwarfs the industry average of 16.7, and the price‑to‑book ratio of –17.6 reflects a negative book value per share. Support sits near $24.01 and resistance near $30.73, giving the shares limited upside on the near‑term chart.
On the fundamentals side, revenue grew 28.8% year‑over‑year to $168 M with strong gross (55%) and operating (35%) margins, and Q1 EPS turned positive at $0.09 after a loss‑making prior year. Operating cash flow of $54.0 M supports the current earnings despite the lack of free cash generation. However, the balance sheet is strained with $227 M of debt against only $10.5 M of cash and a negative book value, resulting in zero ROE and ROA. The company announced a $100 M share repurchase alongside a public offering and targets $195 M of revenue for 2026, which has driven analysts to a consensus “buy” and a median price target of $30.5. Overall, the stock combines solid top‑line growth with considerable valuation and balance‑sheet risks. Given the extreme greed sentiment (Fear & Greed Index 88.7), market participants appear overly optimistic, which could exacerbate price corrections.
On the fundamentals side, revenue grew 28.8% year‑over‑year to $168 M with strong gross (55%) and operating (35%) margins, and Q1 EPS turned positive at $0.09 after a loss‑making prior year. Operating cash flow of $54.0 M supports the current earnings despite the lack of free cash generation. However, the balance sheet is strained with $227 M of debt against only $10.5 M of cash and a negative book value, resulting in zero ROE and ROA. The company announced a $100 M share repurchase alongside a public offering and targets $195 M of revenue for 2026, which has driven analysts to a consensus “buy” and a median price target of $30.5. Overall, the stock combines solid top‑line growth with considerable valuation and balance‑sheet risks. Given the extreme greed sentiment (Fear & Greed Index 88.7), market participants appear overly optimistic, which could exacerbate price corrections.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish MACD signal
- Price near resistance with limited upside
- Significant overvaluation vs DCF
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Revenue growth and improving margins
- Analyst consensus buy and price target above current
- Share repurchase program supporting demand
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Long‑term flood insurance demand and AI‑driven underwriting
- Revenue target of $195M for 2026
- Potential upside if balance‑sheet deleveraging succeeds
Key Metrics & Analysis
Financial Health
Revenue Growth28.80%
Profit Margin20.73%
P/E Ratio42.4
P/B Ratio-17.6
Op. Cash Flow$54.0M
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI51.8
Support$24.01
Resistance$30.73
MA 20$27.17
MA 50$25.09
MA 200$25.17
MACDBearish
VolumeIncreasing
Fear & Greed Index88.73
Valuation
Fair Value$8.13
Target Price$30.25
Upside/Downside11.13%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.85
Volatility72.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.